Top Page
Zymeworks
(NASDAQ:ZYME)
Zymeworks (ZYME) vs. SPDR S&P 500 ETF (SPY)
Zymeworks Business Overview & Revenue Model
Zymeworks Earnings Call Summary
Zymeworks Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 134.48M | 76.30M | 76.01M | 412.48M | 26.68M | 38.95M |
| Gross Profit | 134.48M | 76.30M | -66.98M | 412.48M | 26.68M | -131.94M |
| EBITDA | -53.96M | -108.62M | -120.70M | 142.49M | -206.09M | -183.76M |
| Net Income | -63.43M | -122.69M | -118.67M | 124.34M | -211.84M | -180.55M |
Balance Sheet | ||||||
| Total Assets | 397.27M | 463.09M | 580.88M | 648.73M | 389.13M | 538.38M |
| Cash, Cash Equivalents and Short-Term Investments | 251.93M | 225.78M | 374.33M | 492.23M | 252.61M | 426.35M |
| Total Debt | 18.90M | 18.51M | 26.72M | 28.11M | 32.33M | 8.64M |
| Total Liabilities | 77.20M | 124.32M | 116.07M | 155.77M | 140.04M | 128.45M |
| Stockholders Equity | 320.06M | 338.77M | 464.81M | 492.96M | 249.09M | 409.92M |
Cash Flow | ||||||
| Free Cash Flow | -66.20M | -113.11M | -122.38M | 130.98M | -205.74M | -157.67M |
| Operating Cash Flow | -64.25M | -110.04M | -118.30M | 144.11M | -192.45M | -151.40M |
| Investing Cash Flow | 15.08M | 38.76M | -207.25M | -53.85M | 144.60M | -43.44M |
| Financing Cash Flow | -8.46M | -20.45M | 81.85M | 108.58M | 8.01M | 308.98M |
Zymeworks Technical Analysis
Zymeworks Risk Analysis
Zymeworks Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $2.47B | ― | -68.13% | ― | -8.75% | -8.79% | |
54 Neutral | $1.46B | ― | -18.46% | ― | 116.21% | 43.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.23B | ― | -65.35% | ― | 48.32% | -1.91% | |
43 Neutral | $1.21B | ― | -39.73% | ― | ― | -7.33% | |
42 Neutral | $709.13M | ― | -96.24% | ― | ― | -15.77% | |
33 Underperform | $1.08B | ― | -96.11% | ― | ― | 31.16% |
Zymeworks Corporate Events
In the recent earnings call, Zymeworks presented a mixed yet optimistic outlook. The company showcased strong revenue growth and promising clinical data, suggesting a positive future trajectory. However, challenges such as the discontinuation of a key program and a decrease in cash reserves were also highlighted. Overall, the sentiment was largely positive, driven by increased revenue and encouraging clinical trial results.
Zymeworks Inc., a clinical-stage biotechnology company, focuses on developing novel biotherapeutics for diseases like cancer, inflammation, and autoimmune conditions. In its third quarter of 2025, Zymeworks reported significant progress with its antibody-drug conjugate (ADC) platform, including encouraging Phase 1 data for ZW191 and the commencement of a clinical trial for ZW251. The company also achieved a $25 million development milestone from Johnson & Johnson and earned $1 million in royalties from Jazz and BeOne Medicines. Financially, Zymeworks reported a revenue increase to $27.6 million, driven by milestone achievements, although it still faced a net loss of $19.6 million. Despite this, the company completed $22.7 million in share repurchases, reflecting confidence in its long-term growth. Looking ahead, Zymeworks aims to leverage its strategic partnerships and robust pipeline to drive sustainable growth and shareholder returns, with a projected cash runway extending into the second half of 2027.
In its third-quarter 2025 update, Zymeworks reported significant progress in its clinical trials and financial performance. The company presented encouraging Phase 1 data for ZW191, an ADC targeting folate receptor-⍺, and dosed the first patient in a Phase 1 trial for ZW251 targeting hepatocellular carcinoma. Zymeworks achieved a $25 million milestone from Johnson & Johnson and earned $1 million in royalties from Jazz and BeOne Medicines. The company also completed $22.7 million in share repurchases, strengthening shareholder value. Financially, Zymeworks reported a revenue increase to $27.6 million, driven by milestone revenues, and reduced its net loss to $19.6 million. With cash resources projected to fund operations into the second half of 2027, Zymeworks continues to focus on its partnership-driven business model and next-generation therapies.
The most recent analyst rating on (ZYME) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. announced its participation in upcoming investor conferences, including the Stifel Healthcare Conference in New York and the Jefferies London Healthcare Conference. These engagements reflect Zymeworks’ proactive approach to investor relations and its commitment to advancing its pipeline of innovative biotherapeutics. The company’s participation in these conferences is likely to enhance its visibility in the biotechnology sector and provide opportunities to discuss its strategic initiatives and recent developments with potential investors.
The most recent analyst rating on (ZYME) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks announced promising preliminary results from its Phase 1 trial of ZW191, an antibody-drug conjugate targeting folate receptor-alpha, at the AACR-NCI-EORTC Conference. The study showed a 64% overall response rate in gynecological cancers at doses of 6.4mg/kg and above, with a manageable safety profile, indicating potential for ZW191 in treating advanced solid tumors. The company plans to initiate dose optimization in ovarian cancer by the fourth quarter of 2025, aiming to further evaluate clinical activity and safety, which could enhance its positioning in the cancer treatment market.
The most recent analyst rating on (ZYME) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. announced it will report its third quarter 2025 financial results on November 6, 2025, followed by a conference call and webcast to discuss the results and provide a corporate update. This announcement highlights the company’s ongoing efforts to advance its pipeline of therapeutic candidates and maintain transparency with stakeholders, potentially impacting its market position and investor confidence.
The most recent analyst rating on (ZYME) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks announced the presentation of preliminary data from its Phase 1 trial of ZW191, an antibody-drug conjugate targeting folate receptor-⍺, at an international cancer conference. The data highlights ZW191’s potential in treating advanced solid tumors, including ovarian and lung cancers, and supports the company’s broader ADC portfolio. This development underscores Zymeworks’ commitment to advancing differentiated therapies for challenging cancers, potentially impacting its market positioning and offering new treatment options for patients.
The most recent analyst rating on (ZYME) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. has appointed Dr. Adam Schayowitz as Acting Chief Development Officer to further advance its portfolio of therapeutic candidates and strengthen strategic partnerships. Dr. Schayowitz, with extensive experience in oncology drug development, will work closely with Zymeworks’ R&D and Business Development teams to accelerate the company’s efforts in bringing innovative therapies to market, enhancing its industry positioning and potential impact on patients worldwide.
The most recent analyst rating on (ZYME) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. has announced the discontinuation of the clinical development of ZW171, a T cell engager targeting mesothelin-driven cancers, due to an unfavorable benefit-risk profile observed during the Phase 1 trial. Despite this setback, Zymeworks remains committed to advancing its broader product pipeline, including the ongoing trials for ZW191 and the upcoming trials for ZW251 and ZW209, reflecting the company’s disciplined approach to resource allocation and its focus on candidates with the greatest potential impact.
The most recent analyst rating on (ZYME) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Zymeworks Inc. announced its participation in several upcoming investor conferences, where management will engage in one-on-one meetings and fireside chats. These events provide an opportunity for Zymeworks to showcase its advancements and strategic initiatives, potentially enhancing its visibility and investor relations within the biotechnology sector.
The most recent analyst rating on (ZYME) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
The recent earnings call for Zymeworks showcased a robust financial performance, marked by a significant increase in revenue and a return to net income. The company’s strategic partnerships and clinical advancements have reinforced a positive business momentum, although there are some concerns regarding supply chain planning and the timing of clinical readouts.